Wu L Y, Wu A R, Zhan J
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing.
Zhonghua Fu Chan Ke Za Zhi. 1994 Jun;29(6):340-2, 381-2.
Radioimmunoimaging (RI I) assay with 99mTc labeled anti-CEA monoclonal antibody was performed in 31 patients with suspected primary or recurrent malignant ovarian tumor. The radiation dose raging from 920MBq to 110MBq(1mgIgG) was administered i.v. for each patient. Anterior-posterior views of the pelvis and abdomen were obtained routinely with gamma-camera during 18-24 hour after the application of antibody. The results of RII were compared with the findings in operation or CT examination. Sensitivity in diagnosis was 100% (13/13), specificity was 94%(16/17) and metastatic foci sensitivity was 63%(10/16). The serum CA125 in this study appeared to be correlated with the results of RII. However, in 2 patients with normal serum CA125 titers RII revealed true positive. The preliminary clinical results of RII with 99mTc-MAb showed that RII is a promising method for the detection of malignant ovarian tumors.
对31例疑似原发性或复发性恶性卵巢肿瘤患者进行了用99mTc标记的抗CEA单克隆抗体的放射免疫显像（RII）检测。每位患者静脉注射920MBq至110MBq（1mgIgG）的放射剂量。在注射抗体后的18至24小时内，用γ相机常规获取骨盆和腹部的前后位图像。将RII的结果与手术或CT检查的结果进行比较。诊断的敏感性为100%（13/13），特异性为94%（16/17），转移灶敏感性为63%（10/16）。本研究中血清CA125似乎与RII的结果相关。然而，在2例血清CA125滴度正常的患者中，RII显示为真阳性。99mTc-MAb的RII初步临床结果表明，RII是一种检测恶性卵巢肿瘤的有前景的方法。
